文献速递乳腺癌支持与姑息治疗

基于人群的乳腺癌幸存者队列中心脏功能的长期结局:一项横断面研究

Long-term outcome of cardiac function in a population-based cohort of breast cancer survivors: A cross-sectional study.
PubMed 文献 · Eur J Cancer · 2017-06-08

该横断面研究纳入350例诊断后存活至少5年的乳腺癌幸存者(接受化疗和/或放疗)及350例年龄和全科医生匹配的对照女性,发现幸存者左心室射血分数(LVEF)<54%的患病率为15.3%(52例),对照组为7%(24例),OR为2.4(95%CI 1.4-4.0),且血清NT-proBNP水平升高、心血管疾病诊断和心血管药物使用更常见,校正相关协变量后关联仍存在。

要点

  • 乳腺癌幸存者LVEF<54%者52例(15.3%),对照组24例(7%),OR 2.4(95%CI 1.4-4.0)。
  • 幸存者血清NT-proBNP水平升高,心血管疾病诊断和心血管药物使用较对照更常见。
  • 幸存者LVEF<50%或左心室舒张功能障碍的患病率无显著增加。

核心结论

  • 长期来看,乳腺癌幸存者较匹配对照存在轻度左心室收缩功能障碍、NT-proBNP水平升高和心血管疾病风险增加,即使校正心血管危险因素后仍存在。
  • 作者认为在评估患者心血管风险特征时应考虑既往乳腺癌化疗、放疗或两者。

研究设计与样本

  • 在初级保健机构开展的横断面研究,纳入350例诊断后存活至少5年的乳腺癌幸存者(接受化疗和/或放疗)及350例按年龄和全科医生匹配的女性对照。
  • 主要结局为心脏功能障碍,定义为LVEF<54%和年龄校正的左心室舒张功能减退;次要结局包括血清NT-proBNP水平、新诊断心血管疾病和心血管药物使用。

主要发现

  • 乳腺癌幸存者诊断时中位年龄为63岁(四分位距57-68岁),诊断后中位随访10年(四分位距7-14年)。
  • LVEF<54%见于52例(15.3%)幸存者和24例(7%)对照,OR 2.4(95%CI 1.4-4.0)。
  • LVEF<50%或左心室舒张功能障碍的患病率均无显著增加。
  • 与对照相比,幸存者血清NT-proBNP水平升高,心血管疾病诊断更常见,心血管药物使用更频繁;校正诊断时和随访时的相关协变量后这些关联仍存在。

临床怎么用

  • 作者认为在评估患者心血管风险特征时应考虑既往乳腺癌化疗、放疗或两者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemotherapy and radiotherapy for breast cancer may lead to cardiac dysfunction, but the prevalence of long-term echocardiographic evidence of cardiac dysfunction is unknown among survivors. METHODS: In a cross-sectional study in primary care, we included 350 women who survived breast cancer for at least 5 years after diagnosis (treated with chemotherapy and/or radiotherapy) and 350 matched women (age and primary care physician). The primary outcome was cardiac dysfunction, defined as a left ventricular ejection fraction (LVEF) < 54% and an age-corrected decreased left ventricular (LV) diastolic function. Secondary outcomes included serum N-terminal pro B-type natriuretic peptide (NT-proBNP) levels, newly diagnosed cardiovascular diseases and cardiovascular medication. RESULTS: The median age at diagnosis was 63 (interquartile range (IQR) 57-68) years for the breast cancer survivors. Median follow-up after diagnosis was 10 (IQR 7-14) years. LVEF < 54% was present in 52 (15.3%) survivors and 24 (7%) controls (OR 2.4, 95%CI 1.4-4.0), but there was no significant increased prevalence of either LVEF < 50% or LV diastolic dysfunction. Serum NT-proBNP levels were increased, cardiovascular disease was more frequently diagnosed and cardiovascular medication use was more frequent among survivors compared with controls. These associations remained after adjustment for relevant covariates at diagnosis and at follow-up. CONCLUSIONS: In the long term, breast cancer survivors are at increased risk of mild LV systolic dysfunction, increased NT-proBNP levels, and cardiovascular disease compared with matched controls, even after adjustment for cardiovascular risk factors. Previous breast cancer treatment with chemotherapy, radiotherapy or both should be considered when assessing a patient's cardiovascular risk profile.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Boerman LM, Maass SWMC, van der Meer P, et al. Long-term outcome of cardiac function in a population-based cohort of breast cancer survivors: A cross-sectional study. Eur J Cancer. 2017. PMID: 28601706. doi:10.1016/j.ejca.2017.05.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。